Palmitoyl Tetrapeptide-7: What Rigin Is and How It Works

At a glance

What is palmitoyl tetrapeptide-7?

Palmitoyl tetrapeptide-7 is a peptide of four amino acids (glycine, glutamine, proline, and arginine) joined to palmitic acid to help it penetrate the skin. Its peptide sequence derives from a fragment of immunoglobulin, an immune protein, which is why it is grouped with signal peptides that influence the skin's response rather than ones that directly build collagen. It is made by Sederma under the name Rigin and is the companion peptide to palmitoyl tripeptide-1 in Matrixyl 3000. It is a cosmetic ingredient, not a drug.

How does it work?

Laboratory studies describe palmitoyl tetrapeptide-7 as a signal that reduces inflammatory activity in skin. In cell models it is reported to lower interleukin-6, a messenger involved in inflammation. The rationale is that chronic low-grade inflammation, sometimes called "inflammaging," drives the enzymes that break down collagen, so calming that signaling may help skin keep the appearance of firmness. These are laboratory and manufacturer findings about the peptide's behavior, not a proven clinical outcome. In finished cosmetics the benefit is framed in appearance terms, such as a calmer, firmer, smoother look.

Is it FDA-approved?

No, and it does not need to be. The FDA does not pre-approve cosmetic ingredients. A cosmetic may describe how it affects the look and feel of skin, while a claim to treat inflammation or change the body's structure would make a product a drug. Palmitoyl tetrapeptide-7 is used as a cosmetic ingredient, for the appearance of the skin.

What is it used for?

Palmitoyl tetrapeptide-7 is used in soothing and "anti-aging" serums and creams, typically paired with palmitoyl tripeptide-1 as Matrixyl 3000. The appearance goals are the look of calmer, less red skin and a reduction in the appearance of fine lines, and it is often chosen for sensitive-skin formulas.

What does the research show?

The direct human evidence is limited, for several reasons:

• According to PubMed, the peptide appears in a human study of a multi-peptide serum, but its effect cannot be separated from the other active ingredients.
• The specific efficacy data come largely from manufacturer in-use panels.
• An independent review notes that peptides of this type penetrate skin poorly, a practical limit on real-world performance.
• No independent single-ingredient human trial was found.

What are the side effects?

Palmitoyl tetrapeptide-7 is generally well tolerated on the skin, with low irritation potential, and its soothing framing makes it common in gentle formulas. A patch test remains reasonable for sensitive skin, since individual reactions vary.

Evidence strength

Low research: Its mechanism is supported by laboratory data and its efficacy by manufacturer panels and a confounded combination study, with no sound independent human trial of the ingredient alone.

Sources: a clinical study of a multi-peptide serum (Li et al., Journal of Cosmetic Dermatology, 2023, DOI: 10.1111/jocd.15849); and a review of peptide skin permeability (Mortazavi and Moghimi, International Journal of Cosmetic Science, 2022, DOI: 10.1111/ics.12770), both indexed on PubMed. This document is educational and does not constitute medical advice.